Skip to main content
Premium Trial:

Request an Annual Quote

Simulations Plus Acquires Bioreason for $788K

, Nov. 11 (GenomeWeb News) - Simulations Plus has acquired all assets of Santa Fe, NM-based cheminformatics firm Bioreason in an all-cash transaction worth approximately $788,000.

 

Through the transaction, Simulations Plus acquired software, source code, two patents, trademarks, marketing and sales information, and all other fixed assets.

 

Simulations Plus said that Bioreason's flagship software, ClassPharmer will be integrated into a single product with Sage Informatics ChemTK package.

 

ClassPharmer is currently licensed to over 30 companies in the US, Europe, and Japan.

 

Momoko Beran, chief financial officer of Simulations Plus, said in a statement that Bioreason's assets include nearly $400,000 in accounts receivable from multi-year licenses, "with some of these due as early as this month. Most companies license on an annual basis, and if all licenses that will expire during this fiscal year are renewed, revenues from such licenses would exceed $500,000."

 

This article originally appeared in BioInform, a GenomeWeb News sister publication.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.